As biosimilars hit, EU pharma warns against blanket prescribing

Reuters, 9 March 2017
Authors: Ben Hirschlerand Edmund Blair
“European drugmakers, faced with increasing competition from cut-price copies of complex biotech drugs, cautioned doctors on Thursday to take care when switching patients from an established product to a so-called biosimilar version. The European Medicines Agency has to date approved two dozen biosimilars against just four in the United States.”
Find article here.